We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · May 10, 2022

Effect of Tirzepatide on Liver Fat Content and Abdominal Adipose Tissue in Patients With Type 2 Diabetes

The Lancet Diabetes & Endocrinology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Diabetes & Endocrinology
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Lancet Diabetes Endocrinol 2022 Apr 22;[EPub Ahead of Print], A Gastaldelli, K Cusi, L Fernández Landó, R Bray, B Brouwers, Á Rodríguez

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading